Millions more OTC products recalled by J&J

pharmafile | November 29, 2010 | News story | Manufacturing and Production Benadryl Allergy Fastmelt, J&J, JJ, Johnson & Johnson, Motrin, Rolaids, Tylenol, manufacturing compliance, recalls 

Johnson & Johnson has been forced to announce yet another recall of over-the-counter medicines manufactured at its Fort Washington facility in Pennsylvania, USA, this time citing manufacturing “insufficiencies”.

The voluntary recall involves almost five million packs of McNeil Consumer healthcare brand products.

These include four million packs of children’s Benadryl Allergy Fastmelt tablets distributed in Belize, Barbados, Canada, Puerto Rico, St. Martin, St. Thomas and the US, as well as 800,000 packages of 24-count Junior Strength Motrin caplets distributed in the US only.

“There is no indication that the recalled products do not meet quality standards, and this recall is not being undertaken on the basis of adverse events,” said J&J in a statement.

Meanwhile, McNeil has also recalled 71,000 packs of Extra Strength Rolaids softchews which were manufactured by a third party after consumer complaints of an uncharacteristic consistency or texture, traced to crystallised sugar used in the product. The packs were distributed in the US.

The firm has also had to recall nine million bottles of its Tylenol Cold Multi-Symptom liquid product because of a labeling error. The presence of alcohol from flavouring agents was noted as an inactive ingredient listed on the package, but not on the front panel of the product.

McNeil has already recalled tens of millions of bottles of its children’s over-the-counter pain relief products this year because of manufacturing issues at the Fort Washington facility, which was temporarily shut down in April and is not due to reopen until 2011.

The shutdown led to the loss of around 300 jobs out of the plant’s 400-strong workforce.

Phil Taylor

Related Content

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance …

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products …

Johnson & Johnson to acquire Shockwave Medical

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a …

Latest content